Sutro Biopharma (STRO) Competitors

Annexon (NASDAQ:ANNX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Do analysts recommend ANNX or STRO?

Annexon presently has a consensus target price of $12.50, indicating a potential upside of 419.75%. Sutro Biopharma has a consensus target price of $6.11, indicating a potential upside of 645.64%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sutro Biopharma	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Which has more volatility and risk, ANNX or STRO?

Annexon has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Which has better earnings and valuation, ANNX or STRO?

Annexon has higher earnings, but lower revenue than Sutro Biopharma. Annexon is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$138.20M	-$1.18	-2.04
Sutro Biopharma	$62.04M	1.12	-$227.46M	-$2.98	-0.28

Is ANNX or STRO more profitable?

Annexon has a net margin of 0.00% compared to Sutro Biopharma's net margin of -373.66%. Annexon's return on equity of -54.45% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-54.45%	-46.56%
Sutro Biopharma	-373.66%	-347.60%	-59.46%

Do institutionals & insiders believe in ANNX or STRO?

97.0% of Sutro Biopharma shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media prefer ANNX or STRO?

In the previous week, Sutro Biopharma had 3 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Sutro Biopharma and 3 mentions for Annexon. Sutro Biopharma's average media sentiment score of 0.45 beat Annexon's score of 0.33 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Annexon and Sutro Biopharma tied by winning 7 of the 14 factors compared between the two stocks.